Lack of neuropeptide Y receptor detection in human bladder and prostate

B. J. Davis, M. Goepel, S. Bein, R. Chess-Williams, C. R. Chapple, Martin C. Michel

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Objective. To investigate the presence of functional neuropeptide Y (NPY) receptors in human bladder and prostate (both richly endowed with NPY-containing nerve fibers) using peptide YY (PYY) as the agonist. Materials and methods. Binding studies were conducted using [125I]PYY as the radioligand. Organ-bath studies were performed on isolated tissue strips for direct (postjunctional) contractile effects and for (prejunctional) inhibition of field stimulation effects. Any possible degradation of PYY was determined using high-performance liquid chromatography (HPLC). Results. In the radioligand binding studies no quantifiable specific [125I]PYY binding was detected in human bladder or prostate, while specific high-affinity binding was readily seen in rat cerebral cortex. In organ-bath experiments, PYY (up to 1 μmol/L) caused no contraction of human prostate or bladder, whereas noradrenaline and carbachol, respectively, were effective; the potency or efficacy of noradrenaline and carbachol were not altered by PYY. Field stimulation-induced contraction was not affected by PYY in either human bladder or prostate, but was readily inhibited in rat vas deferens. HPLC detected no relevant PYY degradation by human bladder or prostate homogenates. Conclusion. Human bladder and prostate express only very few if any functional NPY receptors.

Original languageEnglish
Pages (from-to)918-924
Number of pages7
JournalBJU International
Volume85
Issue number7
DOIs
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Neuropeptide Y Receptors
Peptide YY
Prostate
Urinary Bladder
Carbachol
Baths
Norepinephrine
High Pressure Liquid Chromatography
Vas Deferens
Neuropeptide Y
Nerve Fibers
Cerebral Cortex

Cite this

Davis, B. J. ; Goepel, M. ; Bein, S. ; Chess-Williams, R. ; Chapple, C. R. ; Michel, Martin C. / Lack of neuropeptide Y receptor detection in human bladder and prostate. In: BJU International. 2000 ; Vol. 85, No. 7. pp. 918-924.
@article{8a6514d83a064fe8ac7f58ddc6380afc,
title = "Lack of neuropeptide Y receptor detection in human bladder and prostate",
abstract = "Objective. To investigate the presence of functional neuropeptide Y (NPY) receptors in human bladder and prostate (both richly endowed with NPY-containing nerve fibers) using peptide YY (PYY) as the agonist. Materials and methods. Binding studies were conducted using [125I]PYY as the radioligand. Organ-bath studies were performed on isolated tissue strips for direct (postjunctional) contractile effects and for (prejunctional) inhibition of field stimulation effects. Any possible degradation of PYY was determined using high-performance liquid chromatography (HPLC). Results. In the radioligand binding studies no quantifiable specific [125I]PYY binding was detected in human bladder or prostate, while specific high-affinity binding was readily seen in rat cerebral cortex. In organ-bath experiments, PYY (up to 1 μmol/L) caused no contraction of human prostate or bladder, whereas noradrenaline and carbachol, respectively, were effective; the potency or efficacy of noradrenaline and carbachol were not altered by PYY. Field stimulation-induced contraction was not affected by PYY in either human bladder or prostate, but was readily inhibited in rat vas deferens. HPLC detected no relevant PYY degradation by human bladder or prostate homogenates. Conclusion. Human bladder and prostate express only very few if any functional NPY receptors.",
author = "Davis, {B. J.} and M. Goepel and S. Bein and R. Chess-Williams and Chapple, {C. R.} and Michel, {Martin C.}",
year = "2000",
doi = "10.1046/j.1464-410X.2000.00573.x",
language = "English",
volume = "85",
pages = "918--924",
journal = "British Journal of Urology",
issn = "1464-410X",
publisher = "Wiley-Blackwell",
number = "7",

}

Lack of neuropeptide Y receptor detection in human bladder and prostate. / Davis, B. J.; Goepel, M.; Bein, S.; Chess-Williams, R.; Chapple, C. R.; Michel, Martin C.

In: BJU International, Vol. 85, No. 7, 2000, p. 918-924.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Lack of neuropeptide Y receptor detection in human bladder and prostate

AU - Davis, B. J.

AU - Goepel, M.

AU - Bein, S.

AU - Chess-Williams, R.

AU - Chapple, C. R.

AU - Michel, Martin C.

PY - 2000

Y1 - 2000

N2 - Objective. To investigate the presence of functional neuropeptide Y (NPY) receptors in human bladder and prostate (both richly endowed with NPY-containing nerve fibers) using peptide YY (PYY) as the agonist. Materials and methods. Binding studies were conducted using [125I]PYY as the radioligand. Organ-bath studies were performed on isolated tissue strips for direct (postjunctional) contractile effects and for (prejunctional) inhibition of field stimulation effects. Any possible degradation of PYY was determined using high-performance liquid chromatography (HPLC). Results. In the radioligand binding studies no quantifiable specific [125I]PYY binding was detected in human bladder or prostate, while specific high-affinity binding was readily seen in rat cerebral cortex. In organ-bath experiments, PYY (up to 1 μmol/L) caused no contraction of human prostate or bladder, whereas noradrenaline and carbachol, respectively, were effective; the potency or efficacy of noradrenaline and carbachol were not altered by PYY. Field stimulation-induced contraction was not affected by PYY in either human bladder or prostate, but was readily inhibited in rat vas deferens. HPLC detected no relevant PYY degradation by human bladder or prostate homogenates. Conclusion. Human bladder and prostate express only very few if any functional NPY receptors.

AB - Objective. To investigate the presence of functional neuropeptide Y (NPY) receptors in human bladder and prostate (both richly endowed with NPY-containing nerve fibers) using peptide YY (PYY) as the agonist. Materials and methods. Binding studies were conducted using [125I]PYY as the radioligand. Organ-bath studies were performed on isolated tissue strips for direct (postjunctional) contractile effects and for (prejunctional) inhibition of field stimulation effects. Any possible degradation of PYY was determined using high-performance liquid chromatography (HPLC). Results. In the radioligand binding studies no quantifiable specific [125I]PYY binding was detected in human bladder or prostate, while specific high-affinity binding was readily seen in rat cerebral cortex. In organ-bath experiments, PYY (up to 1 μmol/L) caused no contraction of human prostate or bladder, whereas noradrenaline and carbachol, respectively, were effective; the potency or efficacy of noradrenaline and carbachol were not altered by PYY. Field stimulation-induced contraction was not affected by PYY in either human bladder or prostate, but was readily inhibited in rat vas deferens. HPLC detected no relevant PYY degradation by human bladder or prostate homogenates. Conclusion. Human bladder and prostate express only very few if any functional NPY receptors.

UR - http://www.scopus.com/inward/record.url?scp=0034091731&partnerID=8YFLogxK

U2 - 10.1046/j.1464-410X.2000.00573.x

DO - 10.1046/j.1464-410X.2000.00573.x

M3 - Article

VL - 85

SP - 918

EP - 924

JO - British Journal of Urology

JF - British Journal of Urology

SN - 1464-410X

IS - 7

ER -